Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Non-Current Debt (2016 - 2026)

Cumberland Pharmaceuticals' Non-Current Debt history spans 15 years, with the latest figure at $5.2 million for Q4 2025.

  • On a quarterly basis, Non-Current Debt fell 48.5% to $5.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $5.2 million, a 48.5% decrease, with the full-year FY2025 number at $5.2 million, down 48.5% from a year prior.
  • Non-Current Debt hit $5.2 million in Q4 2025 for Cumberland Pharmaceuticals, roughly flat from $5.2 million in the prior quarter.
  • Over the last five years, Non-Current Debt for CPIX hit a ceiling of $20.0 million in Q1 2022 and a floor of $5.2 million in Q1 2025.
  • Historically, Non-Current Debt has averaged $13.0 million across 5 years, with a median of $14.5 million in 2021.
  • Biggest five-year swings in Non-Current Debt: skyrocketed 35.71% in 2022 and later plummeted 67.43% in 2025.
  • Tracing CPIX's Non-Current Debt over 5 years: stood at $15.0 million in 2021, then grew by 8.0% to $16.2 million in 2022, then decreased by 21.09% to $12.8 million in 2023, then dropped by 20.4% to $10.2 million in 2024, then tumbled by 48.5% to $5.2 million in 2025.
  • Business Quant data shows Non-Current Debt for CPIX at $5.2 million in Q4 2025, $5.2 million in Q3 2025, and $5.2 million in Q2 2025.